Curated News
By: NewsRamp Editorial Staff
August 31, 2026

NanoViricides Advances NV-387 for Measles Amid Rising Cases

Discuss on LinkedInDiscuss on X, formerly TwitterDiscuss on SubstackDiscuss on TelegramParticipate in discussion on BlueskyParticipate in discussion on MastodonView history of this news story on GitHub
Original Source

TLDR

  • NNVC's measles drug NV-387 gains FDA designations, positioning it for potential Priority Review Voucher and market edge.
  • NNVC advances NV-387 toward Phase II trials, leveraging host-mimetic nanomedicine and FDA orphan and rare pediatric disease designations.
  • NanoViricides' NV-387 aims to combat rising measles cases, offering hope for a deadly disease with limited treatments.
  • NanoViricides' measles drug, NV-387, shows in vivo efficacy and could earn a Priority Review Voucher, a rare FDA incentive.

Impact - Why it Matters

The resurgence of measles, a highly contagious and potentially fatal disease, underscores an urgent need for effective treatments. NanoViricides' NV-387, with its promising preclinical data and FDA designations, could become a crucial therapeutic option, especially for pediatric populations. If successful, it would address a significant public health gap, as current measles management relies primarily on supportive care and vaccination. Moreover, the potential Priority Review Voucher offers a financial incentive that could accelerate the drug's development and approval, benefiting patients and investors alike.

Summary

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antivirals based on host-mimetic nanomedicine technology, has announced an update on its NV-387 measles treatment program as measles cases continue to rise in the U.S. and globally. The company is developing a Phase II clinical trial protocol to evaluate NV-387 as a treatment for measles and intends to bring the protocol under U.S. Food and Drug Administration (FDA) review through an Investigational New Drug (IND) process. NV-387 has demonstrated strong in vivo activity against lethal measles infection in a humanized animal model and has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Drug (RPDD) Designation from the FDA for the treatment of measles. The RPDD designation could make the company eligible for a Priority Review Voucher upon approval of a qualifying marketing application, provided applicable requirements are met.

NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates are based on intellectual property from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and measles. The company is also developing NV-HHV-1 for shingles, and NV-CoV-2 for COVID-19, with an encapsulated version NV-CoV-2-R. The company holds broad licenses from TheraCour for multiple viral targets and is focused on advancing NV-387 into Phase II human clinical trials.

For more details, visit the full press release at https://ibn.fm/JFyfZ. For the latest news on NanoViricides, see the company's newsroom at https://ibn.fm/NNVC. This update comes from BioMedWire, a communications platform focused on the biotech and life sciences sectors, powered by IBN.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances NV-387 for Measles Amid Rising Cases

Blockchain registration record for this content